Karolina Osińska
Research Subjects
Karolina Osińska has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Michał Kulczak
School of Medicine, Medical University of Silesia, Poniatowskiego 15, 40-055 Katowice, Poland
10 shared publications - Anna Kołcz
School of Medicine, Medical University of Silesia, Poniatowskiego 15, 40-055 Katowice, Poland
9 shared publications - Dawid Studziński
Municipal Hospital in Zabrze, Zamkowa 4, 41-803 Zabrze, Poland
9 shared publications - Marcin Schulz
II Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Marii Skłodowskiej-Curie 10, 41-800 Zabrze, Poland
9 shared publications - Agnieszka Morawa
Municipal Hospital in Zabrze, Zabrze, Poland
8 shared publications - Wiktoria Szkatuła
Provincial Specialist Hospital No. 2 in Jastrzębie-Zdrój, Ave. Jana Pawła II 7; 44-330 Jastrzębie-Zdrój, Poland
4 shared publications
Latest Publications
- Open Access
- 18 July 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 94, 73080
Sports-Related Sudden Cardiac Arrest: Age and Sex Risk Factors
Sports-related sudden cardiac arrest (SRSCA) is defined as a natural out-of-hospital collapse of presumed cardiac origin occurring during or within one hour of moderate-to-vigorous physical exercise. Despite the well-documented cardiovascular benefits of physical activity, vigorous exertion can transiently trigger life-threatening arrhythmias in vulnerable individuals, a phenomenon known as the "paradox of exercise". This scientific review aims to evaluate the combined influence of age and sex on the risk and clinical presentation of SRSCA by synthesizing high-quality evidence from contemporary literature, including 37 original research articles drawn from international registries such as the NCAA, FIFA, and ESCAPE-NET. The analysis reveals a striking and consistent male predominance, with men accounting for 90% to 98% of cases across various registries, while women exhibit a 10- to 13-fold lower incidence rate. Furthermore, the underlying pathological substrates shift significantly with age; inherited or congenital structural diseases like hypertrophic cardiomyopathy and coronary artery anomalies predominate in athletes under 35, whereas atherosclerotic coronary artery disease is the primary cause in those over 35. Survival rates following SRSCA are notably favorable compared to non-sports cardiac arrests, ranging from 45% to over 90% in organized settings, largely due to the witnessed nature of these events and the rapid utilization of automated external defibrillators (AEDs), which is associated with survival as high as 86%. Consequently, reducing the burden of sudden death requires a two-tier strategy: primary prevention through preparticipation screening initiated around age 12 to detect phenotypic manifestations of disease, and secondary prevention via robust emergency preparedness, including mandatory AED access and rehearsed emergency action plans at all sporting venues.
- 18 July 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 94, 73080
Open AccessSports-Related Sudden Cardiac Arrest: Age and Sex Risk Factors
Sports-related sudden cardiac arrest (SRSCA) is defined as a natural out-of-hospital collapse of presumed cardiac origin occurring during or within one hour of moderate-to-vigorous physical exercise. Despite the well-documented cardiovascular benefits of physical activity, vigorous exertion can transiently trigger life-threatening arrhythmias in vulnerable individuals, a phenomenon known as the "paradox of exercise". This scientific review aims to evaluate the combined influence of age and sex on the risk and clinical presentation of SRSCA by synthesizing high-quality evidence from contemporary literature, including 37 original research articles drawn from international registries such as the NCAA, FIFA, and ESCAPE-NET. The analysis reveals a striking and consistent male predominance, with men accounting for 90% to 98% of cases across various registries, while women exhibit a 10- to 13-fold lower incidence rate. Furthermore, the underlying pathological substrates shift significantly with age; inherited or congenital structural diseases like hypertrophic cardiomyopathy and coronary artery anomalies predominate in athletes under 35, whereas atherosclerotic coronary artery disease is the primary cause in those over 35. Survival rates following SRSCA are notably favorable compared to non-sports cardiac arrests, ranging from 45% to over 90% in organized settings, largely due to the witnessed nature of these events and the rapid utilization of automated external defibrillators (AEDs), which is associated with survival as high as 86%. Consequently, reducing the burden of sudden death requires a two-tier strategy: primary prevention through preparticipation screening initiated around age 12 to detect phenotypic manifestations of disease, and secondary prevention via robust emergency preparedness, including mandatory AED access and rehearsed emergency action plans at all sporting venues.
- Open Access
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (2(50))
EFFICACY AND SAFETY OF MAVACAMTEN IN HYPERTROPHIC CARDIOMYOPATHY – A SYSTEMATIC REVIEW OF CURRENT CLINICAL STUDIES
Introduction: Hypertrophic cardiomyopathy (HCM) is an inherited condition characterized by sarcomeric hypercontractility, leading to dynamic left ventricular outflow tract (LVOT) obstruction in approximately 70% of patients. Mavacamten, a first-in-class selective cardiac myosin inhibitor, addresses the underlying molecular cause by reducing excessive actin-myosin cross-bridge formation. Aim: To evaluate the clinical efficacy and safety of mavacamten in symptomatic obstructive HCM (oHCM) using data from randomized trials and real-world studies. Methods: A systematic search of PubMed, Embase, and Cochrane Library identified 110 publications. Following predefined criteria, 44 studies were included in the final analysis, including pivotal phase III trials (EXPLORER-HCM, VALOR-HCM) and long-term extensions. Results: Mavacamten demonstrated a significant reduction in LVOT gradients (mean reduction of ~47 mmHg in EXPLORER-HCM) and improved quality of life, with KCCQ-CSS scores increasing by an average of 14.2 points. Between 60% and 80% of patients achieved ≥1 NYHA functional class improvement. In the VALOR-HCM trial, approximately 90% of patients avoided invasive septal reduction therapy (SRT) through 128 weeks. The primary safety concern was a transient reduction in LVEF (<50%) occurring in 5–14% of patients, which was typically reversible with dose titration. Conclusion: Mavacamten is a transformative non-invasive therapy that shifts oHCM management from palliative care to mechanism-targeted treatment. While highly effective in improving hemodynamics and functional capacity, rigorous echocardiographic monitoring remains mandatory to ensure safety regarding systolic function.
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (2(50))
Open AccessEFFICACY AND SAFETY OF MAVACAMTEN IN HYPERTROPHIC CARDIOMYOPATHY – A SYSTEMATIC REVIEW OF CURRENT CLINICAL STUDIES
Introduction: Hypertrophic cardiomyopathy (HCM) is an inherited condition characterized by sarcomeric hypercontractility, leading to dynamic left ventricular outflow tract (LVOT) obstruction in approximately 70% of patients. Mavacamten, a first-in-class selective cardiac myosin inhibitor, addresses the underlying molecular cause by reducing excessive actin-myosin cross-bridge formation. Aim: To evaluate the clinical efficacy and safety of mavacamten in symptomatic obstructive HCM (oHCM) using data from randomized trials and real-world studies. Methods: A systematic search of PubMed, Embase, and Cochrane Library identified 110 publications. Following predefined criteria, 44 studies were included in the final analysis, including pivotal phase III trials (EXPLORER-HCM, VALOR-HCM) and long-term extensions. Results: Mavacamten demonstrated a significant reduction in LVOT gradients (mean reduction of ~47 mmHg in EXPLORER-HCM) and improved quality of life, with KCCQ-CSS scores increasing by an average of 14.2 points. Between 60% and 80% of patients achieved ≥1 NYHA functional class improvement. In the VALOR-HCM trial, approximately 90% of patients avoided invasive septal reduction therapy (SRT) through 128 weeks. The primary safety concern was a transient reduction in LVEF (<50%) occurring in 5–14% of patients, which was typically reversible with dose titration. Conclusion: Mavacamten is a transformative non-invasive therapy that shifts oHCM management from palliative care to mechanism-targeted treatment. While highly effective in improving hemodynamics and functional capacity, rigorous echocardiographic monitoring remains mandatory to ensure safety regarding systolic function.
- Open Access
- 26 May 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (2(50))
CLINICAL CHARACTERISTICS AND PROGNOSTIC SIGNIFICANCE OF NON-DIPPER HYPERTENSION
Non-dipper hypertension, characterized by a nocturnal blood pressure (BP) decline of less than 10% relative to daytime means, represents a significant clinical phenotype associated with heightened cardiovascular morbidity and mortality. While conventional office measurements often fail to capture these variations, ambulatory blood pressure monitoring (ABPM) has emerged as the gold standard for assessing 24-hour BP variability and identifying circadian rhythm disruptions. This review synthesizes current evidence regarding the clinical profile, pathophysiology, and prognostic impact of the non-dipper pattern. The pathophysiology of non-dipper hypertension involves a complex interplay of autonomic dysregulation, nocturnal renin-angiotensin-aldosterone system hyperactivity, and impaired renal sodium handling. This profile is highly prevalent among patients with metabolic comorbidities, such as type 2 diabetes and obesity, where prevalence rates can reach up to 77%. Prognostically, the non-dipper pattern is a potent independent predictor of target organ damage, including left ventricular hypertrophy, stroke, and chronic kidney disease. Notably, each 5% reduction in nocturnal BP fall is associated with a 20% increase in cardiovascular mortality. Therapeutic management emphasizes personalized chronotherapy specifically bedtime dosing of antihypertensive agents alongside novel pharmacological options like SGLT2 inhibitors and ARNIs. Furthermore, lifestyle interventions such as sodium restriction and the treatment of sleep disorders are crucial for restoring the physiological circadian rhythm. Ultimately, systematic use of ABPM is essential for accurate risk stratification and the implementation of targeted therapies to reduce the global burden of cardiovascular events.
- 26 May 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (2(50))
Open AccessCLINICAL CHARACTERISTICS AND PROGNOSTIC SIGNIFICANCE OF NON-DIPPER HYPERTENSION
Non-dipper hypertension, characterized by a nocturnal blood pressure (BP) decline of less than 10% relative to daytime means, represents a significant clinical phenotype associated with heightened cardiovascular morbidity and mortality. While conventional office measurements often fail to capture these variations, ambulatory blood pressure monitoring (ABPM) has emerged as the gold standard for assessing 24-hour BP variability and identifying circadian rhythm disruptions. This review synthesizes current evidence regarding the clinical profile, pathophysiology, and prognostic impact of the non-dipper pattern. The pathophysiology of non-dipper hypertension involves a complex interplay of autonomic dysregulation, nocturnal renin-angiotensin-aldosterone system hyperactivity, and impaired renal sodium handling. This profile is highly prevalent among patients with metabolic comorbidities, such as type 2 diabetes and obesity, where prevalence rates can reach up to 77%. Prognostically, the non-dipper pattern is a potent independent predictor of target organ damage, including left ventricular hypertrophy, stroke, and chronic kidney disease. Notably, each 5% reduction in nocturnal BP fall is associated with a 20% increase in cardiovascular mortality. Therapeutic management emphasizes personalized chronotherapy specifically bedtime dosing of antihypertensive agents alongside novel pharmacological options like SGLT2 inhibitors and ARNIs. Furthermore, lifestyle interventions such as sodium restriction and the treatment of sleep disorders are crucial for restoring the physiological circadian rhythm. Ultimately, systematic use of ABPM is essential for accurate risk stratification and the implementation of targeted therapies to reduce the global burden of cardiovascular events.
- Open Access
- 26 May 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (2(50))
EFFECTIVENESS AND SAFETY OF ANTI-CGRP MONOCLONAL ANTIBODIES FOR MIGRAINE PREVENTION IN REAL-WORLD PRACTICE: A SYSTEMATIC REVIEW
The transition from Phase III trials to real-world evidence (RWE) is critical for understanding monoclonal antibody (mAb) performance in complex, comorbid populations. This review evaluates the real-world effectiveness and safety of calcitonin gene-related peptide (CGRP) pathway inhibitors in routine clinical practice. A systematic search of PubMed (2021–2026) identified observational studies, including prospective registries (e.g., PEARL, GARLIT, MAB-MIG) and large-scale claims analyses, regarding erenumab, fremanezumab, galcanezumab, and eptinezumab. Synthesis of 32 studies (n > 1 million patients) demonstrates robust effectiveness across diverse populations. Real-world data confirm sustained ≥ 50% responder rates (ranging from 40%–75% in most cohorts) and significant reductions in acute medication use. Benefits were maintained over 12–36 months, even in patients with chronic migraine and medication overuse headaches. Large-scale analyses (MarketScan, Medicare) indicate that CGRP inhibitors are not associated with an increased risk of myocardial infarction or stroke compared to onabotulinumtoxinA, even in older adults. Switching between ligand and receptor targets remains an effective strategy for initial non-responders. RWE establishes that anti-CGRP mAbs provide durable effectiveness and high adherence in difficult-to-treat populations. The data confirm a favorable cardiovascular safety profile, supporting their role as a cornerstone of modern migraine prevention.
- 26 May 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (2(50))
Open AccessEFFECTIVENESS AND SAFETY OF ANTI-CGRP MONOCLONAL ANTIBODIES FOR MIGRAINE PREVENTION IN REAL-WORLD PRACTICE: A SYSTEMATIC REVIEW
The transition from Phase III trials to real-world evidence (RWE) is critical for understanding monoclonal antibody (mAb) performance in complex, comorbid populations. This review evaluates the real-world effectiveness and safety of calcitonin gene-related peptide (CGRP) pathway inhibitors in routine clinical practice. A systematic search of PubMed (2021–2026) identified observational studies, including prospective registries (e.g., PEARL, GARLIT, MAB-MIG) and large-scale claims analyses, regarding erenumab, fremanezumab, galcanezumab, and eptinezumab. Synthesis of 32 studies (n > 1 million patients) demonstrates robust effectiveness across diverse populations. Real-world data confirm sustained ≥ 50% responder rates (ranging from 40%–75% in most cohorts) and significant reductions in acute medication use. Benefits were maintained over 12–36 months, even in patients with chronic migraine and medication overuse headaches. Large-scale analyses (MarketScan, Medicare) indicate that CGRP inhibitors are not associated with an increased risk of myocardial infarction or stroke compared to onabotulinumtoxinA, even in older adults. Switching between ligand and receptor targets remains an effective strategy for initial non-responders. RWE establishes that anti-CGRP mAbs provide durable effectiveness and high adherence in difficult-to-treat populations. The data confirm a favorable cardiovascular safety profile, supporting their role as a cornerstone of modern migraine prevention.
- Open Access
- 24 May 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 56
Sustaining the Quality of Sports Participation and Life Standards in Aging Men: A Systematic Review of Physical Activity and Urological Health Management
This systematic review formulates an organizational service framework integrating clinical urological data with sports management practices to mitigate disease-induced dropout among aging male athletes. Following PRISMA guidelines, a systematic search of PubMed (2021–2026) yielded 22 primary open-access articles evaluating physical activity, sedentary behaviors, and male urological or renal outcomes. High-volume cohort data confirms a robust inverse relationship between regular physical activity and the severity of lower urinary tract symptoms and erectile dysfunction, though extreme training volumes display a non-linear risk threshold. In clinical rehabilitation phases, supervised technological exercises paired with behavioral compliance models significantly accelerate post-surgical continence recovery. Longitudinally, overactive bladder symptoms serve as independent predictors of upper-limb grip strength decline and physical frailty. Sports enterprises can optimize service quality and member retention by moving from generic configurations toward age-appropriate, urologically sustainable exercise designs. Practical administrative interventions include expanding facility restroom accessibility to reduce public anxiety and embedding non-invasive urological screening metrics into routine physical assessments to preserve lifelong functional longevity.
- 24 May 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 56
Open AccessSustaining the Quality of Sports Participation and Life Standards in Aging Men: A Systematic Review of Physical Activity and Urological Health Management
This systematic review formulates an organizational service framework integrating clinical urological data with sports management practices to mitigate disease-induced dropout among aging male athletes. Following PRISMA guidelines, a systematic search of PubMed (2021–2026) yielded 22 primary open-access articles evaluating physical activity, sedentary behaviors, and male urological or renal outcomes. High-volume cohort data confirms a robust inverse relationship between regular physical activity and the severity of lower urinary tract symptoms and erectile dysfunction, though extreme training volumes display a non-linear risk threshold. In clinical rehabilitation phases, supervised technological exercises paired with behavioral compliance models significantly accelerate post-surgical continence recovery. Longitudinally, overactive bladder symptoms serve as independent predictors of upper-limb grip strength decline and physical frailty. Sports enterprises can optimize service quality and member retention by moving from generic configurations toward age-appropriate, urologically sustainable exercise designs. Practical administrative interventions include expanding facility restroom accessibility to reduce public anxiety and embedding non-invasive urological screening metrics into routine physical assessments to preserve lifelong functional longevity.
- Open Access
- 15 May 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (2(50))
MATERNAL OBESITY AS A DETERMINANT OF LONG-TERM OFFSPRING HEALTH: INSIGHTS FROM METABOLIC, CARDIOVASCULAR, AND NEURODEVELOPMENTAL PERSPECTIVES
Introduction and Objective: The prevalence of maternal overweight and obesity has increased dramatically worldwide, posing significant risks for offspring health. Maternal obesity has been associated with multisystemic consequences, including metabolic, cardiovascular, neuroendocrine, renal, and immune disturbances. This review aims to synthesize current evidence on the impact of maternal obesity on offspring health and to identify potential mechanisms underlying these effects. Methods: A comprehensive literature search was conducted in PubMed, Scopus, and Web of Science for studies published up to 2026. Both human epidemiological studies and experimental animal models were included to evaluate the effects of maternal obesity on offspring outcomes. Keywords included “maternal obesity”, “offspring health”, “developmental programming”, “metabolic disorders”, “neurodevelopment”, and “immunology”. Relevant studies were critically assessed, with particular focus on mechanisms, sex-specific effects, and long-term consequences. Results / Methodology: Evidence indicates that maternal obesity programs offspring health through multiple pathways, including altered metabolism, epigenetic modifications, inflammatory processes, and microbiome-mediated effects. Offspring of obese mothers exhibit higher risk of hypertension, insulin resistance, type 2 diabetes, dyslipidemia, impaired renal development, neurodevelopmental and behavioral disorders, and immune dysregulation. These effects are often sex-specific and may persist throughout childhood and adulthood. Both preconception and gestational interventions, including weight management and lifestyle optimization, can partially mitigate these risks. Conclusion: Maternal obesity is a major determinant of long-term multisystem health outcomes in offspring. Understanding the mechanisms of developmental programming is essential for developing preventive strategies, emphasizing the importance of maternal health optimization before and during pregnancy.
- 15 May 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (2(50))
Open AccessMATERNAL OBESITY AS A DETERMINANT OF LONG-TERM OFFSPRING HEALTH: INSIGHTS FROM METABOLIC, CARDIOVASCULAR, AND NEURODEVELOPMENTAL PERSPECTIVES
Introduction and Objective: The prevalence of maternal overweight and obesity has increased dramatically worldwide, posing significant risks for offspring health. Maternal obesity has been associated with multisystemic consequences, including metabolic, cardiovascular, neuroendocrine, renal, and immune disturbances. This review aims to synthesize current evidence on the impact of maternal obesity on offspring health and to identify potential mechanisms underlying these effects. Methods: A comprehensive literature search was conducted in PubMed, Scopus, and Web of Science for studies published up to 2026. Both human epidemiological studies and experimental animal models were included to evaluate the effects of maternal obesity on offspring outcomes. Keywords included “maternal obesity”, “offspring health”, “developmental programming”, “metabolic disorders”, “neurodevelopment”, and “immunology”. Relevant studies were critically assessed, with particular focus on mechanisms, sex-specific effects, and long-term consequences. Results / Methodology: Evidence indicates that maternal obesity programs offspring health through multiple pathways, including altered metabolism, epigenetic modifications, inflammatory processes, and microbiome-mediated effects. Offspring of obese mothers exhibit higher risk of hypertension, insulin resistance, type 2 diabetes, dyslipidemia, impaired renal development, neurodevelopmental and behavioral disorders, and immune dysregulation. These effects are often sex-specific and may persist throughout childhood and adulthood. Both preconception and gestational interventions, including weight management and lifestyle optimization, can partially mitigate these risks. Conclusion: Maternal obesity is a major determinant of long-term multisystem health outcomes in offspring. Understanding the mechanisms of developmental programming is essential for developing preventive strategies, emphasizing the importance of maternal health optimization before and during pregnancy.
- Open Access
- 17 February 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 88
Ankle Sprain: A Common but Often Overlooked Injury – A Review of Causes, Treatment, and Rehabilitation
Introduction: Ankle sprains are a common injury affecting millions of people worldwide. While many cases are mild, they can lead to chronic joint instability, functional limitations and an increased risk of recurrence. Sprains most commonly involve the lateral ligaments of the joint, particularly ATFL, and in more complex cases, may also affect other structures, resulting in the high treatment costs. Aim: The aim of this article is to present modern methods of diagnosis, treatment and rehabilitation of ankle sprains, including innovative therapies and technologies that support recovery. Methods: A search of PubMed, Web of Science and Google Scholar was conducted. Included were randomized controlled trials, systematic review and meta-analyses of ankle sprain treatment and rehabilitation strategies. Results: An ankle sprain, if not treated properly, can lead to chronic instability, functional limitations and the risk of recurrence. Early diagnosis, intervention are crucial. Modern therapeutic methods such as micro-needle knives, electroacupuncture and rehabilitation robots offer promising treatment options. Integration of traditional methods with innovative technologies can speed up rehabilitation, improve joint stability and reduce the risk of recurrence. Conclusion: An ankle sprain, despite its initially mild nature,can lead to long term functional consequences. Early diagnosis and appropriate therapeutic intervention are crucial to minimise the risk of chronic instability and other complications. Modern diagnostic technologies and biological therapies are promising treatment options, accelerating the rehabilitation process and improving functional outcomes. However, these innovative methods require further research and verification of the reliability of the results obtained, as they are still in the early stages of development.
- 17 February 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 88
Open AccessAnkle Sprain: A Common but Often Overlooked Injury – A Review of Causes, Treatment, and Rehabilitation
Introduction: Ankle sprains are a common injury affecting millions of people worldwide. While many cases are mild, they can lead to chronic joint instability, functional limitations and an increased risk of recurrence. Sprains most commonly involve the lateral ligaments of the joint, particularly ATFL, and in more complex cases, may also affect other structures, resulting in the high treatment costs. Aim: The aim of this article is to present modern methods of diagnosis, treatment and rehabilitation of ankle sprains, including innovative therapies and technologies that support recovery. Methods: A search of PubMed, Web of Science and Google Scholar was conducted. Included were randomized controlled trials, systematic review and meta-analyses of ankle sprain treatment and rehabilitation strategies. Results: An ankle sprain, if not treated properly, can lead to chronic instability, functional limitations and the risk of recurrence. Early diagnosis, intervention are crucial. Modern therapeutic methods such as micro-needle knives, electroacupuncture and rehabilitation robots offer promising treatment options. Integration of traditional methods with innovative technologies can speed up rehabilitation, improve joint stability and reduce the risk of recurrence. Conclusion: An ankle sprain, despite its initially mild nature,can lead to long term functional consequences. Early diagnosis and appropriate therapeutic intervention are crucial to minimise the risk of chronic instability and other complications. Modern diagnostic technologies and biological therapies are promising treatment options, accelerating the rehabilitation process and improving functional outcomes. However, these innovative methods require further research and verification of the reliability of the results obtained, as they are still in the early stages of development.
- Open Access
- 13 February 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (1(49))
NEPRILYSIN INHIBITORS (ARNI) IN THE TREATMENT OF CHRONIC HEART FAILURE — A SYSTEMATIC REVIEW AND CRITICAL APPRAISAL OF THE EVIDENCE
Angiotensin receptor–neprilysin inhibitors (ARNI), with sacubitril/valsartan as the prototypical agent, have fundamentally transformed the pharmacological treatment paradigm of chronic heart failure (HF) [6,11,36,47,48,49,50]. This systematic review synthesizes the available clinical evidence, with a particular focus on the therapeutic efficacy of ARNI across the full continuum of left ventricular ejection fraction [3,4,17,50]. In patients with heart failure with reduced ejection fraction (HFrEF), pivotal randomized trials have consistently demonstrated the superiority of ARNI over conventional angiotensin-converting enzyme inhibitors in lowering cardiovascular mortality and HF-related hospitalizations, while also promoting favorable reverse myocardial remodeling [2,9,10,11,18,26,30,39,41,43,44,49]. In contrast, among individuals with preserved or mildly reduced ejection fraction, the principal clinical benefit is reduction in recurrent HF hospitalizations, with numerically greater treatment effects reported in women [1,3,7,18,23]. In addition, sacubitril/valsartan exhibits clinically relevant renoprotective effects and a favorable safety profile in complex patient populations, including those with diabetes mellitus or advanced chronic kidney disease [4,10,11,18]. Contemporary clinical guidelines position ARNI as a cornerstone of quadruple guideline-directed medical therapy, recommending early initiation during hospitalization and proactive dose up-titration to optimize clinical outcomes [7,8,11,13,21,31,47,48,49,50]. Addressing barriers to implementation—such as treatment-related hypotension and therapeutic inertia—remains essential to reduce the considerable global burden of heart failure [5,7,28,29,34,38].
- 13 February 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (1(49))
Open AccessNEPRILYSIN INHIBITORS (ARNI) IN THE TREATMENT OF CHRONIC HEART FAILURE — A SYSTEMATIC REVIEW AND CRITICAL APPRAISAL OF THE EVIDENCE
Angiotensin receptor–neprilysin inhibitors (ARNI), with sacubitril/valsartan as the prototypical agent, have fundamentally transformed the pharmacological treatment paradigm of chronic heart failure (HF) [6,11,36,47,48,49,50]. This systematic review synthesizes the available clinical evidence, with a particular focus on the therapeutic efficacy of ARNI across the full continuum of left ventricular ejection fraction [3,4,17,50]. In patients with heart failure with reduced ejection fraction (HFrEF), pivotal randomized trials have consistently demonstrated the superiority of ARNI over conventional angiotensin-converting enzyme inhibitors in lowering cardiovascular mortality and HF-related hospitalizations, while also promoting favorable reverse myocardial remodeling [2,9,10,11,18,26,30,39,41,43,44,49]. In contrast, among individuals with preserved or mildly reduced ejection fraction, the principal clinical benefit is reduction in recurrent HF hospitalizations, with numerically greater treatment effects reported in women [1,3,7,18,23]. In addition, sacubitril/valsartan exhibits clinically relevant renoprotective effects and a favorable safety profile in complex patient populations, including those with diabetes mellitus or advanced chronic kidney disease [4,10,11,18]. Contemporary clinical guidelines position ARNI as a cornerstone of quadruple guideline-directed medical therapy, recommending early initiation during hospitalization and proactive dose up-titration to optimize clinical outcomes [7,8,11,13,21,31,47,48,49,50]. Addressing barriers to implementation—such as treatment-related hypotension and therapeutic inertia—remains essential to reduce the considerable global burden of heart failure [5,7,28,29,34,38].
- Open Access
- 30 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (1(49))
IMMUNOMODULATORY EFFECTS OF VITAMIN D AND ITS STATUS IN PATIENTS WITH AUTOIMMUNE DISEASES
The incidence of autoimmune diseases is increasing year by year, especially in Western societies. Many factors, both genetic and environmental, are involved, and vitamin D (vD, 25(OH)D3) deficiency is considered to be one of the key factors. However, the precise etiopathogenesis of autoimmune disorders is still not fully understood, which is also reflected in the limitation of therapeutic possibilities. Recently, there has been a growing interest in the role of vitamin D in alleviating autoimmunological processes, as vD has the ability to stimulate or inhibit virtually every stage of the immune response through its vitamin D receptor (VDR), expressed on immune cells. Innate and adaptive immune system and endothelial membrane stability. This allows us to define this vitamin as a strong immunomodulator in terms of both innate and acquired immunity. The aim of this paper is to present the pathophysiology of selected autoimmune diseases and to demonstrate the modifying properties of vitamin D on the immune system. Our review also demonstrates the scale of deficiency, both in the general population and among individuals diagnosed with autoimmune disease.
- 30 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (1(49))
Open AccessIMMUNOMODULATORY EFFECTS OF VITAMIN D AND ITS STATUS IN PATIENTS WITH AUTOIMMUNE DISEASES
The incidence of autoimmune diseases is increasing year by year, especially in Western societies. Many factors, both genetic and environmental, are involved, and vitamin D (vD, 25(OH)D3) deficiency is considered to be one of the key factors. However, the precise etiopathogenesis of autoimmune disorders is still not fully understood, which is also reflected in the limitation of therapeutic possibilities. Recently, there has been a growing interest in the role of vitamin D in alleviating autoimmunological processes, as vD has the ability to stimulate or inhibit virtually every stage of the immune response through its vitamin D receptor (VDR), expressed on immune cells. Innate and adaptive immune system and endothelial membrane stability. This allows us to define this vitamin as a strong immunomodulator in terms of both innate and acquired immunity. The aim of this paper is to present the pathophysiology of selected autoimmune diseases and to demonstrate the modifying properties of vitamin D on the immune system. Our review also demonstrates the scale of deficiency, both in the general population and among individuals diagnosed with autoimmune disease.
- Open Access
- 21 December 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (4(48))
LEVOSIMENDAN AS BRIDGING THERAPY IN ADVANCED HEART FAILURE: CURRENT STATE OF KNOWLEDGE AND CLINICAL PERSPECTIVES
Advanced heart failure (AHF) constitutes a terminal expression of cardiovascular disease, associated with severe, refractory symptoms and high mortality despite optimized medical therapy. Levosimendan, a first-in-class inodilator, addresses this challenge, acting as a calcium sensitizer and potassium channel opener. Its unique tripartite mechanism provides positive inotropy independently of the cAMP pathway, critically avoiding increased intracellular calcium or myocardial oxygen demand. The active metabolite, OR-1896, ensures prolonged hemodynamic benefits lasting up to two weeks, supporting intermittent, outpatient bridging strategies. This systematic literature review synthesized current evidence by applying a rigorous search strategy across biomedical databases, resulting in the inclusion of 32 scientific publications encompassing high-level evidence such as meta-analyses, randomized controlled trials (RCTs), and cohort studies. Pooled analyses suggest that repetitive levosimendan administration significantly improves Left Ventricular Ejection Fraction (LVEF), reduces NT-proBNP levels, and is associated with a reduced risk of all-cause mortality (RR 0.60). Furthermore, it confers vital organoprotective effects, notably improving renal function in patients awaiting heart transplantation (HTx), and its preoperative use as a "bridge to transplant" (BTT) is deemed safe. Despite compelling data from small RCTs (e.g., LION-HEART), the field requires larger, definitive studies—such as the ongoing LEIA-HF trial—to establish the precise role of levosimendan in contemporary AHF management.
- 21 December 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (4(48))
Open AccessLEVOSIMENDAN AS BRIDGING THERAPY IN ADVANCED HEART FAILURE: CURRENT STATE OF KNOWLEDGE AND CLINICAL PERSPECTIVES
Advanced heart failure (AHF) constitutes a terminal expression of cardiovascular disease, associated with severe, refractory symptoms and high mortality despite optimized medical therapy. Levosimendan, a first-in-class inodilator, addresses this challenge, acting as a calcium sensitizer and potassium channel opener. Its unique tripartite mechanism provides positive inotropy independently of the cAMP pathway, critically avoiding increased intracellular calcium or myocardial oxygen demand. The active metabolite, OR-1896, ensures prolonged hemodynamic benefits lasting up to two weeks, supporting intermittent, outpatient bridging strategies. This systematic literature review synthesized current evidence by applying a rigorous search strategy across biomedical databases, resulting in the inclusion of 32 scientific publications encompassing high-level evidence such as meta-analyses, randomized controlled trials (RCTs), and cohort studies. Pooled analyses suggest that repetitive levosimendan administration significantly improves Left Ventricular Ejection Fraction (LVEF), reduces NT-proBNP levels, and is associated with a reduced risk of all-cause mortality (RR 0.60). Furthermore, it confers vital organoprotective effects, notably improving renal function in patients awaiting heart transplantation (HTx), and its preoperative use as a "bridge to transplant" (BTT) is deemed safe. Despite compelling data from small RCTs (e.g., LION-HEART), the field requires larger, definitive studies—such as the ongoing LEIA-HF trial—to establish the precise role of levosimendan in contemporary AHF management.